Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

NCT00964795 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

323

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Intravitreal Aflibercept Injection 2mg

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]